Press Releases
Advancing Biopharma Innovations: BIO 2025 Highlights
Samsung Biologics took part in the 2025 BIO International Convention held between June 16-19 in Boston. The company shared about Samsung Organoids, end-to-end ADC services, and operational excellence through technological innovations. The team connected with existing and potential clients throughout the four-day event.
Samsung Organoids, the company’s new research services, streamline preclinical development to accelerate investigational new drug filing timelines through data-driven analysis of candidate molecules. The organoid-based services were launched earlier this week, paving the way for clients to advance drug discovery through precision screening. By expanding into preclinical research, Samsung Biologics plans to better support the full drug lifecycle.
Through a large curved screen at the Samsung Biologics booth on the main exhibition floor, the team also shared updates regarding Plant 5, showcasing the company’s commitment to biologics manufacturing. Plant 5 brings up the company’s total biomanufacturing capacity to 784,000 liters. Technological innovation, overall digitalization, and logistics automation allow operators to focus on quality operations. Furthermore, real-time data sharing with clients gives them visibility of bioprocesses as they would see in their own facilities.
ADC and multispecific antibody services, as well as pre-filled syringe drug product manufacturing capabilities, were also discussed.
The booth had meeting rooms to facilitate conversations with existing and potential clients to share more about the company’s offerings and discuss collaboration opportunities in research, development, and manufacturing.
CEO and President John Rim held a press conference to share about the company’s growth strategies toward a pure-play CDMO.
The company’s senior executives also actively engaged with the visitors and media.
The company’s presence was seen throughout the exhibition center, with a sky bridge banner and staircase graphic focused on advancing multiple modalities to the next stage.
Samsung Biologics thanks all who connected with the team during BIO 2025 to explore partnership opportunities. Find out more about Samsung Organoids, end-to-end ADC services, and automation advances at our website: samsungbiologics.com
Quality embedded, excellence delivered.
Related Content
Press Release Samsung Biologics launches drug screening services, Samsung Organoids
Samsung BIO Insight Harmonized toward ADC expertise
Samsung BIO Insight Plant 5: Re-shaping biopharma operations
Samsung Biologics took part in the 2025 BIO International Convention held between June 16-19 in Boston. The company shared about Samsung Organoids, end-to-end ADC services, and operational excellence through technological innovations. The team connected with existing and potential clients throughout the four-day event.
Samsung Organoids, the company’s new research services, streamline preclinical development to accelerate investigational new drug filing timelines through data-driven analysis of candidate molecules. The organoid-based services were launched earlier this week, paving the way for clients to advance drug discovery through precision screening. By expanding into preclinical research, Samsung Biologics plans to better support the full drug lifecycle.
Through a large curved screen at the Samsung Biologics booth on the main exhibition floor, the team also shared updates regarding Plant 5, showcasing the company’s commitment to biologics manufacturing. Plant 5 brings up the company’s total biomanufacturing capacity to 784,000 liters. Technological innovation, overall digitalization, and logistics automation allow operators to focus on quality operations. Furthermore, real-time data sharing with clients gives them visibility of bioprocesses as they would see in their own facilities.
ADC and multispecific antibody services, as well as pre-filled syringe drug product manufacturing capabilities, were also discussed.
The booth had meeting rooms to facilitate conversations with existing and potential clients to share more about the company’s offerings and discuss collaboration opportunities in research, development, and manufacturing.
CEO and President John Rim held a press conference to share about the company’s growth strategies toward a pure-play CDMO.
The company’s senior executives also actively engaged with the visitors and media.
The company’s presence was seen throughout the exhibition center, with a sky bridge banner and staircase graphic focused on advancing multiple modalities to the next stage.
Samsung Biologics thanks all who connected with the team during BIO 2025 to explore partnership opportunities. Find out more about Samsung Organoids, end-to-end ADC services, and automation advances at our website: samsungbiologics.com
Quality embedded, excellence delivered.
Related Content
Press Release Samsung Biologics launches drug screening services, Samsung Organoids
Samsung BIO Insight Harmonized toward ADC expertise
Samsung BIO Insight Plant 5: Re-shaping biopharma operations